Online Only Articles

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase

Department of Hematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy
Hematology, S.Eugenio Hospital, Rome, Italy
IRCCS Cà Granda Policlinico, Milan, Italy
Careggi Hospital, Florence, Italy
Department of Hematology, Pesaro, Italy
Department of Hematology, Frosinone, Italy
S.Giovanni Battista Hospital, Turin, Italy
Department of Hematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy
Vol. 101 No. 6 (2016): June, 2016 https://doi.org/10.3324/haematol.2016.145623